ArticleJAACAP open2024
Medications for Opioid Use Disorder Among Transition Age Youth Compared to Adults 26 or Older in Rural Settings.
Article in JAACAP open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04418453 (Rural Expansion of Medication Treatment for Opioid Use Disorder), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rural Expansion of Medication Treatment for Opioid Use Disorder (Rural MOUD): Phase 1 Feasibility Study (CTN-0102)
Who cites it
1 citing paper in PubMed.
- Opioid use disorder medications among youth in primary care: Subgroup analysis of the PROUD trial.Pediatrics open scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objective: Transition age youth (TAY), aged 18 to 25 years, face barriers to medication treatment for opioid use disorder (MOUD), resulting in lower retention. We evaluated OUD prevalence and MOUD receipt comparing TAY to adults aged 26 or older residing in rural settings. Method: Electronic health records (October 2019 to January 2021) for 36,762 patients across 6 primary care clinics involved in a large feasibility trial in US rural communities were analyzed. All clinics implemented a standardized intervention. Mixed effects logistic/linear regression estimated the odds of OUD diagnosis among all patients, and, among those with OUD, the odds of receiving MOUD and days prescribed MOUD during the 15-month study period, comparing age categories (TAY aged 18-25 years vs adults 26 years or older). Covariates included gender, race, ethnicity, mental health comorbidities, and insurance status. Results: OUD prevalence was 2.82% among TAY (n = 3,122) and 3.24% among adults aged 26 or older (n = 33,208). After adjusting for covariates and clustering, TAY had significantly lower odds of OUD diagnosis compared to adults 26 years or older (odds ratio = 0.58, 95% CI 0.45-0.73). There were no significant differences in MOUD receipt between age groups. Compared to adults aged 26 or older, TAY with OUD had significantly fewer MOUD days during the study, -43.81 days (-76.85 to -10.77). Conclusion: Although no differences were observed in MOUD prescription receipt between TAY and adults aged 26 or older, TAY with OUD had fewer total days prescribed MOUD, indicating lower retention. Further research generalizable to rural communities is needed to assess retention among rural TAY with OUD. Clinical trial registration information: Rural MOUD Telemedicine in Primary Care Phase 1 (Feasibility); https://clinicaltrials.gov/; NCT04418453.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.